ANX-042 Healthy Volunteer Dose Escalation Study

Trial Profile

ANX-042 Healthy Volunteer Dose Escalation Study

Phase of Trial: Phase I

Latest Information Update: 17 Oct 2017

At a glance

  • Drugs ANX 042 (Primary)
  • Indications Acute heart failure; Chronic heart failure; Decompensated heart failure
  • Focus Adverse reactions; First in man
  • Sponsors Anexon
  • Most Recent Events

    • 18 Nov 2013 Results presented at the 86th Annual Scientific Sessions of the American Heart Association.
    • 01 Dec 2012 Status changed from recruiting to completed as reported by
    • 05 Nov 2012 Planned number of patients changed from 18 to 30 as reported by
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top